2024
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer
Kumar V, Yochum Z, Devadassan P, Huang E, Miller E, Baruwal R, Rumde P, GaitherDavis A, Stabile L, Burns T. TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene 2024, 43: 1431-1444. PMID: 38485737, PMCID: PMC11068584, DOI: 10.1038/s41388-024-02987-5.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsTKI resistanceMET amplificationEpithelial-mesenchymal transitionMET tyrosine kinase inhibitorsOvercome resistanceTyrosine kinase inhibitor resistanceTargetable oncogenic driversResistance in vitroEffective therapeutic strategySuppression of p27Inhibition of Twist1MET alterationsPDX modelsMET pathwayHGF/MET pathwayOncogenic driversLung cancerLung tumorigenesisKinase inhibitorsP27 expressionTherapeutic strategiesPharmacological inhibitionDownstream mediatorTwist1
2023
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.
Tripathi A, Tangen C, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Pal S, Shuch B. Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial. Journal Of Clinical Oncology 2023, 41: 4562-4562. DOI: 10.1200/jco.2023.41.16_suppl.4562.Peer-Reviewed Original ResearchProgression-free survivalPositive predictive valueCentral pathology reviewCentral reviewPathology reviewHistologic subtypeType 1PRCC subtypesAdvanced papillary renal cell carcinomaPathologic concordance rateLines of therapyPapillary renal cell carcinomaSubset of patientsType 2 tumorGreater clinical benefitRenal cell carcinomaLimited clinical valueType 2 diseaseExpert genitourinary pathologistsLocal reviewClassification of subtypesSunitinib armMET alterationsClinical outcomesClinical benefit
2019
The HGF-MET signaling pathway is enriched in LUAC brain metastases.
Velez M, Yochum Z, Chandran U, Chakka A, Bhattacharya S, Somasundaram A, LaFramboise W, Wallweber G, Ravanera R, Kurland B, Dacic S, Stabile L, Burns T. The HGF-MET signaling pathway is enriched in LUAC brain metastases. Journal Of Clinical Oncology 2019, 37: e20597-e20597. DOI: 10.1200/jco.2019.37.15_suppl.e20597.Peer-Reviewed Original ResearchBrain metastasesHepatocyte growth factorEpithelial-mesenchymal transitionMET amplificationEMT markersNon-small cell lung cancer patientsLung adenocarcinoma brain metastasisMET activationCell lung cancer patientsLung cancer patientsPaired samplesSubset of casesMET alterationsMET-TKIPoor prognosisCancer patientsPrimary tumorMET inhibitorsEMT transcription factorsMET expressionMetastasisPrimary siteMolecular alterationsPathogenic variantsC-Met
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply